Alignment Healthcare (NASDAQ:ALHC) Stock Price Target Lowered at JPMorgan Chase & Co.

Alignment Healthcare (NASDAQ:ALHC) had its price target cut by equities researchers at JPMorgan Chase & Co. from $10.00 to $8.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 10.04% from the company’s current price.

A number of other brokerages also recently commented on ALHC. Barclays reduced their price objective on shares of Alignment Healthcare from $10.00 to $9.00 and set an “equal weight” rating for the company in a research report on Friday. Piper Sandler reiterated an “overweight” rating and issued a $15.00 price target on shares of Alignment Healthcare in a research report on Friday. Needham & Company LLC began coverage on shares of Alignment Healthcare in a research report on Wednesday. They issued a “hold” rating for the company. UBS Group cut their price objective on shares of Alignment Healthcare from $22.00 to $9.00 and set a “neutral” rating on the stock in a report on Monday, October 12th. Finally, William Blair cut shares of Alignment Healthcare from an “outperform” rating to a “market perform” rating in a research report on Friday, October 9th. Six research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat.com, Alignment Healthcare currently has a consensus rating of “Hold” and a consensus price target of $14.27.

Alignment Healthcare Trading Down 9.8%

NASDAQ ALHC traded down $0.79 on Friday, reaching $7.27. The stock had a trading volume of 13,820,261 shares, compared to its average volume of 5,666,000. The company has a quick ratio of 1.70, a current ratio of 1.70 and a debt-to-equity ratio of 1.22. The stock has a fifty day moving average price of $9.99 and a two-hundred day moving average price of $16.89. Alignment Healthcare has a 12-month low of $6.01 and a 12-month high of $25.12. The firm has a market capitalization of $1.51 billion, a price-to-earnings ratio of 38.27 and a beta of 1.14.

Alignment Healthcare (NASDAQ:ALHC) last released its earnings results on Thursday, October 29th. The company reported ($0.04) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.04). The firm had revenue of $1.36 billion for the quarter, compared to analyst estimates of $1.31 billion. Alignment Healthcare had a net margin of 0.89% and a return on equity of 20.02%. The business’s quarterly revenue was up 36.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.02 earnings per share. As a group, sell-side analysts forecast that Alignment Healthcare will post 0.14 EPS for the current fiscal year.

Insider Activity at Alignment Healthcare

In related news, insider Hyong Kim sold 32,479 shares of Alignment Healthcare stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $8.30, for a total transaction of $269,575.70. Following the transaction, the insider directly owned 299,271 shares of the company’s stock, valued at $2,483,949.30. The trade was a 9.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Dawn Maroney sold 122,707 shares of the stock in a transaction on Friday, September 11th. The shares were sold at an average price of $12.68, for a total value of $1,555,924.76. Following the sale, the president owned 794,606 shares of the company’s stock, valued at $10,075,604.08. This trade represents a 13.38% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 1,061,967 shares of company stock worth $13,642,490. 5.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Alignment Healthcare

A number of large investors have recently added to or reduced their stakes in ALHC. Oregon Public Employees Retirement Fund grew its holdings in Alignment Healthcare by 11.7% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 41,900 shares of the company’s stock worth $342,000 after acquiring an additional 4,400 shares during the period. Vise Technologies Inc. boosted its stake in Alignment Healthcare by 31.2% during the 3rd quarter. Vise Technologies Inc. now owns 12,163 shares of the company’s stock worth $99,000 after acquiring an additional 2,894 shares during the last quarter. VestGen Advisors LLC bought a new position in Alignment Healthcare during the 3rd quarter worth approximately $135,000. Park Avenue Securities LLC grew its holdings in Alignment Healthcare by 37.2% during the third quarter. Park Avenue Securities LLC now owns 59,635 shares of the company’s stock valued at $487,000 after purchasing an additional 16,157 shares during the period. Finally, Sterling Capital Management LLC grew its holdings in Alignment Healthcare by 839.9% during the third quarter. Sterling Capital Management LLC now owns 6,739 shares of the company’s stock valued at $55,000 after purchasing an additional 6,022 shares during the period. Institutional investors own 86.19% of the company’s stock.

Key Alignment Healthcare News

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Alignment reported third-quarter revenue of $1.36 billion, up 36.7% year over year and above the $1.31 billion analyst estimate. Adjusted EPS of a $0.04 loss matched consensus. Alignment Healthcare Reports Third Quarter 2026 Results
• Positive Sentiment: Management is targeting at least 20% top-line growth in 2027, supporting the company’s longer-term expansion narrative. Alignment Targets 2027 Growth
• Neutral Sentiment: Barclays reduced its price target from $10 to $9 while maintaining an “equal weight” rating, implying potential upside but limited conviction. Barclays Rating
• Negative Sentiment: Alignment lowered its 2026 adjusted EBITDA outlook to at least $100 million, signaling weaker near-term profitability and helping offset the revenue beat. Alignment EBITDA Outlook
• Negative Sentiment: CMS reduced the 2027 Star Rating for Alignment’s California HMO contract H3815 from 4.0 to 3.5 stars. The contract serves approximately 75% of membership, raising concerns about bonus eligibility, enrollment and reimbursement economics. Alignment H3815 CMS Rating Concerns
• Negative Sentiment: KeyCorp downgraded ALHC from “overweight” to “sector weight,” while multiple law firms announced investigations into possible securities-law violations. These notices are allegations and do not establish wrongdoing, but they add reputational and legal overhang. Alignment Investigation Notice

About Alignment Healthcare

Alignment Healthcare, Inc is a technology-enabled health insurance company focused on providing Medicare Advantage plans for seniors. The company combines health plan coverage with care coordination and clinical services designed to help members manage chronic conditions, access providers and navigate the health care system.

Its offerings include Medicare Advantage plans, supplemental benefits and member support services. Alignment also uses its proprietary technology platform, including the Alignment Virtual Application (AVA), to support care teams, analyze health information and help deliver more personalized services to members.

Founded in 2013, Alignment Healthcare serves Medicare-eligible consumers in selected markets, including California, Florida, Nevada and North Carolina.